GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 66.76 USD | +0.91% |
|
-1.92% | -17.59% |
| Apr. 19 | Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says | MT |
| Apr. 19 | BMO Capital Adjusts Price Target on Gilead Sciences to $80 From $89 | MT |
Financials (USD)
| Sales 2024 * | 27.51B | Sales 2025 * | 28.02B | Capitalization | 82.5B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.73B | Net income 2025 * | 6.84B | EV / Sales 2024 * | 3.51 x |
| Net Debt 2024 * | 14.01B | Net Debt 2025 * | 8.23B | EV / Sales 2025 * | 3.24 x |
| P/E ratio 2024 * |
29.5
x | P/E ratio 2025 * |
12
x | Employees | 18,000 |
| Yield 2024 * |
4.74% | Yield 2025 * |
4.95% | Free-Float | 99.9% |
More Fundamentals
* Assessed data
More news
Latest transcript on Gilead Sciences, Inc.
More recommendations
More press releases
More news
| 1 day | +0.91% | ||
| 1 week | -1.46% | ||
| Current month | -8.86% | ||
| 1 month | -9.76% | ||
| 3 months | -14.88% | ||
| 6 months | -14.19% | ||
| Current year | -17.59% |
1 week
65.90
68.46
1 month
65.9074.28
Current year
65.9087.87
1 year
65.9087.87
3 years
57.1789.74
5 years
56.5689.74
10 years
56.56123.37
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 58 | 19-02-28 |
Andrew Dickinson
DFI | Director of Finance/CFO | 54 | 15-12-31 |
Flavius Martin
CTO | Chief Tech/Sci/R&D Officer | - | 21-04-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anthony Welters
BRD | Director/Board Member | 69 | 20-10-16 |
| Director/Board Member | 71 | 17-12-31 | |
Ted Love
BRD | Director/Board Member | 65 | Jan. 31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.99% | 215 M€ | +13.63% | - | |
| 8.10% | 0 M€ | 0.00% | - | |
| 8.06% | 0 M€ | 0.00% | - | |
| 5.23% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 66.76 | +0.91% | 10,656,956 |
| 24-04-18 | 66.16 | -1.15% | 6,442,224 |
| 24-04-17 | 66.93 | -0.56% | 5,287,730 |
| 24-04-16 | 67.31 | -0.65% | 4,975,048 |
| 24-04-15 | 67.75 | -0.47% | 7,717,826 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotes
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
66.16
USD
Average target price
85.25
USD
Spread / Average Target
+28.85%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.59% | 82.5B | |
| +24.60% | 672B | |
| +24.08% | 550B | |
| -5.63% | 351B | |
| +15.37% | 317B | |
| +7.38% | 292B | |
| +3.26% | 211B | |
| +0.78% | 203B | |
| -9.69% | 144B | |
| -6.63% | 141B |
- Stock Market
- Equities
- GILD Stock
